356
|
Yang , J. , Liu , X.X. , Fan , H. , Tang , Q. , Shou , Z.X. , Zuo , D.M. et al. ( 2015 ) Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis . PLoS One , 10 ( 10 ), e0140551 .
Zhang , L. , Li , Y. , Guan , C.Y. , Tian , S. , Lv , X.D. , Li , J.H. et al. ( 2018 )
Therapeutic effect of human umbilical cord- derived mesenchymal stem cells on injured rat endometrium during its chronic phase . Stem Cell Research & Therapy , 9 , 36 .
Zuo , W. , Xie , B. , Li , C. , Yan , Y. , Zhang , Y. , Liu , W. et al. ( 2018 ) The clinical ap- plications of endometrial mesenchymal stem cells . Biopreservation and Biobanking , 16 , 158 – 164 .
Zycosan®
(pentosan polysulfate sodium injection) 250 mg/mL
For intramuscular use in horses only.
Brief Summary (For Full Prescribing Information, see package insert) CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION: Zycosan contains pentosan polysulfate sodium, a semi- synthetic polysulfated xylan.
It is a pale yellow to brownish yellow, clear, sterile solution. INDICATION: For the control of clinical signs associated with osteoarthritis in horses. CONTRAINDICATIONS: Horses with hypersensitivity to pentosan polysulfate sodium or any of the inactive ingredients in Zycosan should not receive Zycosan. Do not use Zycosan concurrently with other anticoagulant drugs. Do not use in horses with clotting disorders or within 24 hours of surgical procedures (see Warnings and Precautions). WARNINGS AND PRECAUTIONS:
User Safety Warnings: Not for use in humans. Keep out of reach of children. Pentosan polysulfate sodium is a weak anticoagulant. Caution should be used when administering Zycosan if you are taking an anticoagulant. In case of accidental self-injection, seek immediate medical attention. If product comes into contact with skin, rinse skin thoroughly with water and seek medical attention if needed. To obtain a Safety Data Sheet (SDS), contact Dechra at (866) 933-2472. Animal Safety Warnings and Precautions:
Zycosan has been shown to prolong coagulation parameters up to 24 hours after injection, therefore caution should be used when administering this drug before or after strenuous activities (see Target Animal Safety). Due to the anticoagulant effects, this drug may exacerbate Exercise Induced Pulmonary Hemorrhage (EIPH). The concurrent use of NSAIDs with Zycosan has not been evaluated.
ABDELNABY ET AL.
How to cite this article: Abdelnaby , E.A. , Abdallah , A.N. , Anwar , I.M. , El- Tookhy , O.S. & Shamaa , A.A. ( 2024 ) The therapeutic effect of stem cell- derived exosomes in the treatment of chronic endometritis as assessed by histopathological, Doppler and hormonal expression in Arabian mares . Equine Veterinary Education , 36 , 347 – 356 . Available from:
https://doi.org/10.1111/eve.13888
Due to the anticoagulant effects of Zycosan and known anticoagulant effects of some NSAIDs, caution should be used if NSAIDs are concurrently administered. Horses concurrently treated with Zycosan and NSAIDs should be monitored for hemorrhage or other clinical signs of abnormal bleeding (e.g., petechiae, ecchymosis, or epistaxis). The safety of long-term repeat use of Zycosan has not been evaluated. Pigmentary changes in the retina (pigmentary maculopathy) have been reported in human patients following long-term oral use of pentosan polysulfate sodium. It is not known if a similar finding occurs in horses. The safe use of Zycosan has not been evaluated in breeding, pregnant, or lactating horses. Other Warnings:
Do not use in horses intended for human consumption. ADVERSE REACTIONS:
Injection site reactions were the most frequently reported adverse reactions in the field study. Injection site reactions were associated with clinicopathology changes in some cases. Other adverse reactions reported in more than one horse were prolongation of coagulation parameters (activated partial thromboplastin time (aPTT) and prothrombin time (PT)), lethargy, behavior changes, and colic. To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Dechra at (866) 933-2472 . For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at
http://www.fda.gov/reportanimalae. STORAGE CONDITIONS: Store at room temperature 68-77°F (20-25°C), with excursions to 59-86°F (15-30°C). MANUFACTURED FOR: Dechra Veterinary Products 7015 College Boulevard, Suite 525 Overland Park, KS 66211 USA
Approved by FDA under NADA # 141-559 Zycosan is a trademark of Dechra Limited. R 01 2023
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
